Exploring InflaRx N.V. (IFRX) Investor Profile: Who’s Buying and Why?

Ever wondered who's investing in InflaRx N.V. (IFRX), and more importantly, why? As of April 2025, a total of 34 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a collective 13,676,734 shares. Are these investments driven by the company's potential in pioneering anti-inflammatory therapeutics, or are there other factors at play? With major shareholders including Suvretta Capital Management, Llc, 683 Capital Management, LLC, and Morgan Stanley, understanding their motivations could unlock valuable insights into the future of IFRX. Dive in to explore the investor profile of InflaRx and uncover the reasons behind their strategic moves.

InflaRx N.V. (IFRX) Who Invests in InflaRx N.V. (IFRX) and Why?

Understanding the investor profile of InflaRx N.V. (IFRX) provides valuable insights into the market's perception of the company. Investors are attracted to InflaRx N.V. (IFRX) for various reasons, influenced by the company's growth prospects, strategic market position, and the potential of its innovative therapies.

Key investor types in InflaRx N.V. (IFRX) typically include:

• Retail Investors: Individual investors who buy and sell shares for their own accounts.
• Institutional Investors: Entities such as mutual funds, pension funds, and insurance companies that invest on behalf of their clients.
• Hedge Funds: Investment partnerships that use pooled funds and employ different strategies to earn active return, or alpha, for their investors.

These investors are drawn to InflaRx N.V. (IFRX) due to several factors:

• Growth Prospects: The potential for significant revenue increase driven by the success of its clinical programs.
• Market Position: InflaRx N.V. (IFRX)'s focus on novel therapeutics targeting the complement system positions it uniquely in the biotechnology sector.

Investment strategies among InflaRx N.V. (IFRX) investors vary:

• Long-Term Holding: Investors who believe in the company's long-term potential and hold shares for an extended period.
• Short-Term Trading: Traders who aim to profit from short-term price fluctuations.
• Value Investing: Investors who seek to invest in companies that they believe are undervalued by the market.

Examining the ownership structure can further reveal the composition of InflaRx N.V. (IFRX)'s investor base. While specific, up-to-the-minute details on exact shareholding percentages can fluctuate, regulatory filings typically offer a view of major institutional holders.

The motivations behind investing in InflaRx N.V. (IFRX) are closely tied to the company’s activities and progress. Investors monitor several key indicators:

• Clinical Trial Results: Positive outcomes from clinical trials can significantly boost investor confidence.
• Regulatory Milestones: Approval of new therapies by regulatory bodies such as the FDA or EMA.
• Partnerships and Collaborations: Strategic alliances with other companies can validate InflaRx N.V. (IFRX)'s technology and expand its market reach.

To gain more insight into the company's goals, review Mission Statement, Vision, & Core Values of InflaRx N.V. (IFRX).

Understanding these aspects helps stakeholders gauge the overall investor sentiment and the potential trajectory of InflaRx N.V. (IFRX) in the market.

InflaRx N.V. (IFRX) Institutional Ownership and Major Shareholders of InflaRx N.V. (IFRX)

Understanding the ownership structure of InflaRx N.V. (IFRX) can provide valuable insights into the company's stability, strategic direction, and potential stock performance. Institutional investors and major shareholders often wield significant influence due to the size of their holdings, making their activity a key area of interest for potential and current investors.

Top Institutional Investors: Identifying the top institutional investors in InflaRx N.V. (IFRX) offers a glimpse into who has the most significant stake in the company's success. These entities typically include mutual funds, hedge funds, pension funds, and other large investment firms. While specific, up-to-the-minute data on institutional holdings can fluctuate, examining recent filings and financial news reports can reveal the major players. Keep in mind that ownership percentages can change frequently.

As of the latest information available, here's what you should consider regarding InflaRx N.V. (IFRX)'s institutional ownership:

• Information on specific institutional investors and their exact shareholdings in InflaRx N.V. (IFRX) can be found in regulatory filings such as 13F filings with the Securities and Exchange Commission (SEC). These filings are required for institutional investment managers with over $100 million in assets under management and are filed quarterly.
• Major institutional investors may include well-known investment firms specializing in the healthcare or biotechnology sectors. Reviewing their portfolios and investment strategies can provide context on why they hold a stake in InflaRx N.V. (IFRX).

Changes in Ownership: Monitoring changes in institutional ownership can signal shifts in sentiment toward InflaRx N.V. (IFRX). Increases in institutional holdings may suggest growing confidence in the company's prospects, while decreases could indicate concerns about future performance.

• Investors should pay attention to trends in institutional ownership over time. Are institutional investors, on balance, increasing or decreasing their positions in InflaRx N.V. (IFRX)?
• Significant changes in ownership by key institutional investors can sometimes precede major news or events related to the company.

Impact of Institutional Investors: The presence and actions of large institutional investors can have a notable impact on InflaRx N.V. (IFRX)'s stock price and overall strategy. Their trading activity can create buying or selling pressure, influencing short-term price movements. Additionally, institutional investors often engage with company management and exert influence on corporate governance and strategic decisions.

• High institutional ownership can sometimes reduce stock volatility, as these investors tend to have a longer-term investment horizon.
• However, large institutional positions can also create the risk of significant sell-offs if these investors lose confidence in the company.
• The views and opinions of major institutional shareholders can shape the narrative around InflaRx N.V. (IFRX), influencing investor sentiment and market perception.

Institutional investors play a crucial role in the financial markets, and their activity in InflaRx N.V. (IFRX) is worth monitoring for anyone interested in the company's performance. By tracking who owns the stock and how their positions are changing, investors can gain valuable insights into the factors driving InflaRx N.V. (IFRX)'s stock price and strategic direction.

For further insights into InflaRx N.V. (IFRX)'s financial standing, consider exploring Breaking Down InflaRx N.V. (IFRX) Financial Health: Key Insights for Investors.

InflaRx N.V. (IFRX) Key Investors and Their Impact on InflaRx N.V. (IFRX)

Understanding the investor profile of InflaRx N.V. (IFRX) provides valuable insights into the company's stability, strategic direction, and potential stock movements. Key investors can range from institutional owners and hedge funds to individual shareholders, each wielding varying degrees of influence.

As of April 2025, 34 institutional owners and shareholders have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC), holding a total of 13,676,734 shares in InflaRx N.V. (IFRX).

• Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.
• The Schedule 13D indicates that the investor holds (or held) more than 5% of the company and intends (or intended) to actively pursue a change in business strategy.
• Schedule 13G indicates a passive investment of over 5%.

Here's an overview of some notable investors:

• Suvretta Capital Management, Llc: Among the largest shareholders.
• 683 Capital Management, LLC: Another significant institutional holder.
• Morgan Stanley: Holds a substantial number of shares, with recent increases in their position. In Q4 2024, Morgan Stanley added 1,370,035 shares, representing a 205.1% increase to their portfolio.
• Northern Trust Corp: A major institutional investor.
• Raymond James Financial Inc: Indicates a notable investment.
• Ubs Oconnor Llc: Another institutional investor with a considerable stake. OCONNOR, a distinct business unit of UBS Asset Management Americas (LLC), added 76,108 shares (+10.5%) to their portfolio in Q3 2024.
• Eversept Partners, LP: An involved institutional owner.
• Raymond James Financial Services Advisors, Inc.: Shows continuous interest.
• Raymond James & Associates: Reinforces the financial interest in InflaRx N.V. (IFRX).
• Boothbay Fund Management, Llc: Represents another institutional position.

These major shareholders can exert influence through their voting rights and potential engagement with the company's management regarding strategic decisions.

Recent moves by institutional investors reflect changing sentiments and strategic adjustments:

• Woodline Partners LP: Significantly decreased their position by removing 173,586 shares (-100.0%) in Q3 2024.
• Morgan Stanley: Reduced their holdings by 159,700 shares (-19.3%) in Q3 2024, before increasing their position significantly in Q4 2024.

These transactions can sometimes influence stock price and investor confidence.

The fund sentiment score, which ranges from 0 to 100, indicates the level of institutional accumulation, with higher numbers suggesting greater accumulation. Monitoring this score can provide insights into the overall institutional sentiment towards InflaRx N.V. (IFRX).

Institutional investors often use put/call ratios to gauge sentiment. Put options indicate negative sentiment, while call options suggest positive sentiment. The historical put/call ratio can reveal overall institutional sentiment, overcoming deficiencies of merely tracking total institutional ownership.

While there's no explicit mention of activist investors in the provided context, Schedule 13D filings would indicate investors intending to actively pursue changes in business strategy, which could signal activist involvement.

The share price of InflaRx N.V. (IFRX) has seen some volatility. On April 15, 2025, the share price was $1.10. Previously, on April 16, 2024, it was $1.31, marking a 16.03% decrease. Recent data from April 21, 2025, shows the stock price at $1.095. The stock's 52-week range is between $0.8238 and $2.815.

Recent news and analyst ratings also play a crucial role:

• Guggenheim Securities increased its price target for InflaRx N.V. (IFRX) to $10 from $7, maintaining a Buy rating.
• H.C. Wainwright reiterated a Buy rating on the stock with a $8.00 price target.
• Wall Street analysts rate InflaRx N.V. (IFRX) as Very Bullish on average.

These ratings reflect confidence in InflaRx N.V. (IFRX)'s pipeline and strategic direction.

For more information on InflaRx N.V. (IFRX), you might find this link helpful: InflaRx N.V. (IFRX): History, Ownership, Mission, How It Works & Makes Money

InflaRx N.V. (IFRX) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions to InflaRx N.V. (IFRX) is crucial for assessing the company's current standing and future prospects. Recent market dynamics and analyst perspectives provide valuable insights into how major shareholders influence the stock's performance.

Investor sentiment toward InflaRx N.V. (IFRX) can be gauged by observing the behavior of its major shareholders. While specific sentiments (positive, neutral, or negative) can fluctuate, significant changes in ownership often trigger market reactions. For example, substantial acquisitions by institutional investors might signal confidence in the company's potential, leading to a positive market response. Conversely, large sell-offs could indicate concerns, resulting in a negative impact on the stock price.

Recent market reactions to changes in ownership or large investor moves can be seen in InflaRx N.V. (IFRX)'s stock performance. Monitoring stock charts and news releases around the dates of significant investor activities can reveal how the market interprets these changes. Positive clinical trial results, strategic partnerships, or regulatory approvals can also drive investor interest and market value.

Analyst perspectives play a vital role in shaping investor sentiment. Analysts often provide ratings (e.g., buy, hold, sell) and price targets based on their assessment of the company's financials, pipeline, and market conditions. These insights can influence both current shareholders and potential investors.

Key factors that analysts might focus on include:

• Clinical Trial Progress: Updates on the status and results of clinical trials for InflaRx N.V. (IFRX)'s drug candidates.
• Regulatory Milestones: Approvals or rejections from regulatory bodies like the FDA and EMA.
• Financial Health: Assessment of the company’s cash reserves, burn rate, and ability to fund ongoing operations.
• Market Opportunity: Evaluation of the potential market size and competitive landscape for its products.

To illustrate the potential impact of these factors, consider the following hypothetical scenario:

Understanding the history, ownership structure, mission, and business model of InflaRx N.V. (IFRX) can provide a deeper context for assessing investor sentiment and market reactions. More information can be found at: InflaRx N.V. (IFRX): History, Ownership, Mission, How It Works & Makes Money